Volume 13 Issue 6
Nov.  2022
Turn off MathJax
Article Contents
Article Navigation >  ORGAN TRANSPLANTATION  > 2022  >  13(6): 803-809
Jia Yanan, Zhu Jiqiao, Li Han, et al. Clinical application investigation of quantitative evaluation system of immune status in guiding individualized management of immunosuppressants after liver transplantation[J]. ORGAN TRANSPLANTATION, 2022, 13(6): 803-809. doi: 10.3969/j.issn.1674-7445.2022.06.017
Citation: Jia Yanan, Zhu Jiqiao, Li Han, et al. Clinical application investigation of quantitative evaluation system of immune status in guiding individualized management of immunosuppressants after liver transplantation[J]. ORGAN TRANSPLANTATION, 2022, 13(6): 803-809. doi: 10.3969/j.issn.1674-7445.2022.06.017
shu

Clinical application investigation of quantitative evaluation system of immune status in guiding individualized management of immunosuppressants after liver transplantation

doi: 10.3969/j.issn.1674-7445.2022.06.017

  • Department of Hepatobiliary-pancreatic-splenic Surgery, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100020, China

More Information
  • Corresponding author: Li Xianliang, Email: lixianliangbjcy@126.com
  • Received Date: 2022-07-25
    Available Online: 2022-11-14
  • Publish Date: 2022-11-15
    Abstract
  •   Objective  To investigate the guiding role of quantitative evaluation system of immune status in the individualized management of immunosuppressants for the recipients after liver transplantation.  Methods  Clinical data of 239 liver transplant recipients were retrospectively analyzed. MingDao Immune Cell Analysis (MICA) was established. All recipients were divided into two groups according to the adjustment regimens of immunosuppressants. The immunosuppressant regimen was adjusted according to MingDao Immune System Score (MISS) in the MISS group (n=84), and the medication plan was empirically adjusted during the same period in the control group (n=155). According to the time of postoperative detection (t), the recipients in the MISS group were divided into subgroup A (t ≤ 28 d, n=78), subgroup B (28 d < t ≤ 6 months, n=68), subgroup C (6 months < t ≤ 12 months, n=18), subgroup D (12 months < t ≤ 24 months, n=18) and subgroup E (t > 24 months, n=19). In the MISS group, postoperative MISS scores of recipients in subgroups A-E were analyzed. The incidence of acute rejection and opportunistic infection and the overall survival rate were statistically compared between the MISS and control groups.  Results  The MISS scores in subgroups A-E were -7.0 (-13.2, -2.0), -2.0 (-5.8, 1.8), -0.5 (-7.3, 2.8), -2.0 (-4.5, 3.3) and -3.0 (-6.0, 1.0), respectively. The immune status of the recipients was gradually improved over postoperative time, and the difference between two groups was statistically significant (P < 0.05). In the MISS group, 15% (13/84) of the recipients developed acute rejection, and 27% (42/155) in the control group, and the difference was statistically significant (P < 0.05). In the MISS group, the MISS score of the recipients with acute rejection was 0 (-2.5, 3.5), and -5.0 (-12.0, -1.0) for their counterparts without acute rejection, and the difference was statistically significant (P < 0.05). In the MISS group, 2% (2/84) of the recipients presented with postoperative opportunistic infection, and 9% (14/155) in the control group, and the difference was statistically significant (P < 0.05). In the MISS group, the 1- and 3-year overall survival rates were 86.9% and 79.8%, and 83.2% and 76.8% in the control group, and no significant difference was observed between two groups (P > 0.05).  Conclusions  MICA and MISS score may reflect the immune status of liver transplant recipients, and guide the individualized management of administration of immunosuppressants after liver transplantation.

     

    • FullText(HTML)
  • loading
    • References(29)
  • [1]
    KONDA P, GOLAMARI R, EISEN HJ. Novel immunosuppression in solid organ transplantation[J]. Handb Exp Pharmacol, 2022, 272: 267-285. DOI: 10.1007/164_2021_569.
    [2]
    DE MARTIN E, LONDOÑO MC, EMAMAULLEE J, et al. The optimal immunosuppression management to prevent early rejection after liver transplantation: a systematic review of the literature and expert panel recommendations[J]. Clin Transplant, 2022, DOI: 10.1111/ctr.14614[Epubaheadofprint].
    [3]
    SHAKED A, DESMARAIS MR, KOPETSKIE H, et al. Outcomes of immunosuppression minimization and withdrawal early after liver transplantation[J]. Am J Transplant, 2019, 19(5): 1397-1409. DOI: 10.1111/ajt.15205.
    [4]
    SHARMA P, SUN Y, NEAL J, et al. Renal outcomes of liver transplantation recipients receiving standard immunosuppression and early renal sparing immunosuppression: a retrospective single center study[J]. Transplant Direct, 2019, 5(9): e480. DOI: 10.1097/TXD.0000000000000917.
    [5]
    OLSON JC. Immunosuppressive drugs and associated complications in abdominal organ transplantation[J]. Curr Opin Crit Care, 2022, 28(2): 208-215. DOI: 10.1097/MCC.0000000000000927.
    [6]
    PINHEIRO RS, ANDRAUS W, ROMEIRO FG, et al. Model for establishing a new liver transplantation center through mentorship from a university with transplantation expertise[J]. PLoS One, 2022, 17(3): e0266361. DOI: 10.1371/journal.pone.0266361.
    [7]
    BRUNET M, VAN GELDER T, ÅSBERG A, et al. Therapeutic drug monitoring of tacrolimus-personalized therapy: second consensus report[J]. Ther Drug Monit, 2019, 41(3): 261-307. DOI: 10.1097/FTD.0000000000000640.
    [8]
    CHARLTON M, LEVITSKY J, AQEL B, et al. International liver transplantation society consensus statement on immunosuppression in liver transplant recipients[J]. Transplantation, 2018, 102(5): 727-743. DOI: 10.1097/TP.0000000000002147.
    [9]
    寇建涛, 李先亮, 朱继巧, 等. 自创免疫状态量化评分标准评估肝移植受者术后免疫状态的可行性分析[J]. 中华器官移植杂志, 2020, 41(6): 362-366. DOI: 10.3760/cma.j.cn421203-20191110-00407.

    KOU JT, LI XL, ZHU JQ, et al. Application of Mingdao immune score system for evaluating the immune status of liver transplant recipients[J]. Chin J Organ Transplant, 2020, 41(6): 362-366. DOI: 10.3760/cma.j.cn421203-20191110-00407.
    [10]
    李先亮, 贾亚男, 王若麟, 等. 创新免疫状态评估体系的建立及其在疾病诊疗中的应用[J]. 中国现代医学杂志, 2021, 31(16): 1-6. DOI: 10.3969/j.issn.1005-8982.2021.16.001.

    LI XL, JIA YN, WANG RL, et al. Research progress in novel approaches to immune status evaluation and their application in clinical practice[J]. China J Mod Med, 2021, 31(16): 1-6. DOI: 10.3969/j.issn.1005-8982.2021.16.001.
    [11]
    SHEN B, CEN Z, TAN M, et al. Current status of malignant tumors after organ transplantation[J]. Biomed Res Int, 2022: 5852451. DOI: 10.1155/2022/5852451.
    [12]
    JUCAUD V, SHAKED A, DESMARAIS M, et al. Prevalence and impact of de novo donor-specific antibodies during a multicenter immunosuppression withdrawal trial in adult liver transplant recipients[J]. Hepatology, 2019, 69(3): 1273-1286. DOI: 10.1002/hep.30281.
    [13]
    GILL RG, LIN CM. Linking innate immunity and chronic antibody-mediated allograft rejection[J]. Curr Opin Organ Transplant, 2019, 24(6): 694-698. DOI: 10.1097/MOT.0000000000000708.
    [14]
    NEUBERGER J. Immunosuppression in gastroenterology and hepatology[J]. Best Pract Res Clin Gastroenterol, 2021, 54/55: 101758. DOI: 10.1016/j.bpg.2021.101758.
    [15]
    DASHTI-KHAVIDAKI S, SAIDI R, LU H. Current status of glucocorticoid usage in solid organ transplantation[J]. World J Transplant, 2021, 11(11): 443-465. DOI: 10.5500/wjt.v11.i11.443.
    [16]
    PONTICELLI C, GLASSOCK RJ. Prevention of complications from use of conventional immunosuppressants: a critical review[J]. J Nephrol, 2019, 32(6): 851-870. DOI: 10.1007/s40620-019-00602-5.
    [17]
    REZAHOSSEINI O, MØLLER DL, KNUDSEN AD, et al. Use of T cell mediated immune functional assays for adjustment of immunosuppressive or anti-infective agents in solid organ transplant recipients: a systematic review[J]. Front Immunol, 2020, 11: 567715. DOI: 10.3389/fimmu.2020.567715.
    [18]
    DI MAIRA T, LITTLE EC, BERENGUER M. Immunosuppression in liver transplant[J]. Best Pract Res Clin Gastroenterol, 2020, 46/47: 101681. DOI: 10.1016/j.bpg.2020.101681.
    [19]
    MONDANELLI G, BIANCHI R, PALLOTTA MT, et al. A relay pathway between arginine and tryptophan metabolism confers immunosuppressive properties on dendritic cells[J]. Immunity, 2017, 46(2): 233-244. DOI: 10.1016/j.immuni.2017.01.005.
    [20]
    BRAMI I, INI D, SASSONKER N, et al. Immunosuppressive drugs alter α1-antitrypsin production in hepatocytes: implications for epithelial gap repair[J]. Biol Blood Marrow Transplant, 2020, 26(4): 625-633. DOI: 10.1016/j.bbmt.2019.12.764.
    [21]
    MARTIN-MORENO PL, TRIPATHI S, CHANDRAKER A. Regulatory T cells and kidney transplantation[J]. Clin J Am Soc Nephrol, 2018, 13(11): 1760-1764. DOI: 10.2215/CJN.01750218.
    [22]
    PERNOT S, TERME M, RADOSEVIC-ROBIN N, et al. Infiltrating and peripheral immune cell analysis in advanced gastric cancer according to the Lauren classification and its prognostic significance[J]. Gastric Cancer, 2020, 23(1): 73-81. DOI: 10.1007/s10120-019-00983-3.
    [23]
    HARTMANN FJ, BABDOR J, GHERARDINI PF, et al. Comprehensive immune monitoring of clinical trials to advance human immunotherapy[J]. Cell Rep, 2019, 28(3): 819-831. DOI: 10.1016/j.celrep.2019.06.049.
    [24]
    KUMAR D, HUMAR A. CMV immune monitoring-where do we go from here?[J]. Am J Transplant, 2020, 20(8): 1961-1962. DOI: 10.1111/ajt.15875.
    [25]
    SLOWIK V, LERRET SM, LOBRITTO SJ, et al. Variation in immunosuppression practices among pediatric liver transplant centers-society of pediatric liver transplantation survey results[J]. Pediatr Transplant, 2021, 25(2): e13873. DOI: 10.1111/petr.13873.
    [26]
    BAKHTIYAR S, BATRA A, MALIK T, et al. Three decades' analysis of pediatric liver transplantation outcomes reveals limited long-term improvements[J]. Pediatr Transplant, 2022, 26(2): e14158. DOI: 10.1111/petr.14158.
    [27]
    AKBULUT S, SAHIN TT. Comment on: acute rejection after liver transplantation is less common, but predicts better prognosis in HBV-related hepatocellular carcinoma patients[J]. Int J Surg Case Rep, 2021, 84: 106073. DOI: 10.1016/j.ijscr.2021.106073.
    [28]
    HUSSAINI T, TURGEON RD, PARTOVI N, et al. Immunosuppression practices in liver transplantation: a survey of north American centers[J]. Exp Clin Transplant, 2018, 16(5): 550-553. DOI: 10.6002/ect.2017.0096.
    [29]
    TASDOGAN BE, MA M, SIMSEK C, et al. Update on immunosuppression in liver transplantation[J]. Euroasian J Hepatogastroenterol, 2019, 9(2): 96-101. DOI: 10.5005/jp-journals-10018-1301.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(4)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (322) PDF downloads(100) Cited by()
    Proportional views
    Related

    WeChat Subscription Account

    Wechat Service Account

    Contact Us
    • Tel：020-38736410
    • Email: organtranspl@163.com
    • Address：The Third Affiliated Hospital of Sun Yat-sen University, No. 600, Tianhe Road, Tianhe District, Guangzhou
    • Editorial Office of Organ Transplantation  粤ICP备2021030844号
    Links

    Supported by: Beijing Renhe Information Technology Co. Ltd    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return